A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

Phase 2 Active not recruiting 123 enrolled Chengdu Suncadia Medicine Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA nephropathy.

Timeline

Start: 2023-12-19
Primary completion: 2024-12-01
Completion: 2025-08-31

Publications

Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-5965	Small molecule	—	—

A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

Summary

Timeline

Publications

Drugs

Indications